jetcityimage/iStock Editorial via Getty Images Eli Lilly’s (NYSE:LLY) weight loss therapy tirzepatide will be available in Britain starting this week as the U.K. drug store chains Superdrug and Simple Online Pharmacy announced their plans to roll out the popular GLP-1 agonist used for both obesity and diabetes.

英国连锁药店Superdrug和Simple Online Pharmacy宣布计划推出广受欢迎的GLP-1激动剂，用于治疗肥胖症和糖尿病。本周，礼来公司（纽约证券交易所代码：LLY）的减肥疗法tirzepatide将在英国上市。

The rollout comes weeks after the U.K. drug regulator Medicines and Healthcare products Regulatory Agency (MHRA) authorized LLY’s “KwikPen,” an injection pen designed for the convenient delivery of four weekly subcutaneous shots in one device. At the time, the Indiana-based drugmaker said Britain would be the first major market where tirzepatide would be available in KwikPen format, and its supplies would begin within weeks.

几周前，英国药物监管机构药品和保健产品监管局（MHRA）批准了LLY的“KwikPen”，这是一种注射笔，用于在一个设备中方便地每周进行四次皮下注射。当时，这家总部位于印第安纳州的制药商表示，英国将是第一个以奎克彭（KwikPen）形式提供替罗西肽的主要市场，其供应将在数周内开始。

Superdrug is launching tirzepatide at £215 ($270) for 2.5 mg and 5 mg starter doses under its private service on Thursday. The drug branded as Mounjaro for diabetes and Zepbound for obesity in the U.S. has already been made available at Simple Online Pharmacy for £189 ($237) for starter doses. In December, Lilly (LLY) launched Zepbound at a list price of approximately $1,060 for all six dose levels.

Superdrug将于周四在其私人服务下以215英镑（270美元）的价格推出2.5毫克和5毫克起始剂量的替罗巴肽。该药在美国被命名为Mounjaro治疗糖尿病和Zepbound治疗肥胖症，已在Simple Online Pharmacy以189英镑（237美元）的起始剂量上市。去年12月，礼来（LLY）推出了Zepbound，六种剂量水平的标价约为1060美元。

More on Eli Lilly Eli Lilly: Overvaluation Is A Big Red Flag Will Eli Lilly and Company Become A Trillion-Dollar Baby? Eli Lilly and Company: Even 'Miracle Drugs' Can't Keep Stock Rising (Downgrade) Eli Lilly partner BioAge wins $170M to study Zepbound combo Federal judge dismisses PhRMA challenge to Medicare price negotiations .

更多关于礼来的信息礼来：估值过高是一个巨大的危险信号礼来和公司会成为万亿美元的婴儿吗？礼来公司（Eli Lilly and Company）：即使是“神奇药物”也无法保持股价上涨（降级）礼来合作伙伴BioAge赢得1.7亿美元研究Zepbound combo联邦法官驳回PhRMA对医疗保险价格谈判的挑战。